Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU).
• Brand Names Available In United States: Adrucil (injection), Efudex (topical cream), Carac (topical cream), Fluoroplex (topical legacy), Tolak (lotion).
• ATC Code: L01BC02 (Antineoplastic agents → Antimetabolites → Pyrimidine analogues).
• Forms & Dosages: Injection vials (250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL); topical creams/lotions 0.5%–5% in 20–40 g tubes; topical solutions/lotion 0.5% and 4%.
• Manufacturers In United States: AbbVie (Carac), Tolmar (Tolak), Bristol‑Myers Squibb (Adrucil origin), plus generic suppliers such as Teva, Mylan, Sandoz, Pfizer and others.
• Registration Status In United States: FDA approved for topical and IV use as prescription medication.
• OTC / Rx Classification: Prescription only (Rx); not available over‑the‑counter.

Key Findings From Recent Trials

Worried about whether new research makes fluorouracil safer or more effective?

Recent clinical research from 2022–2026 focused on three main areas: DPYD‑guided dosing to reduce severe 5‑FU toxicity, head‑to‑head comparisons of topical fluorouracil versus alternatives for actinic keratosis, and optimizing systemic combinations for colorectal cancer.

Trials evaluating DPYD testing showed dose reductions informed by genotype lowered rates of grade ≥3 toxicities and fewer hospitalizations.

Topical fluorouracil retained robust lesion clearance in actinic keratosis studies while producing predictable local inflammation compared with imiquimod and photodynamic therapy.

Systemic combination research emphasized schedule optimization such as bolus versus infusion timing and added supportive care to limit myelosuppression when 5‑FU is paired with targeted agents.

Regulatory bodies and oncology consortia increasingly endorse DPYD pre‑testing for high‑dose protocols based on accumulated safety signals.

Safety monitoring and standardized supportive measures were common trial recommendations to minimize GI and hematologic complications with systemic 5‑FU.

Clinical Mechanism Of Action

Want a clear explanation of how fluorouracil works against abnormal cells?

Fluorouracil is a pyrimidine analogue that fools rapidly dividing cells into using a faulty building block, which blocks DNA and RNA synthesis and causes controlled cell death.

Inside cells 5‑FU converts to active metabolites such as FdUMP that inhibit thymidylate synthase (TS), depleting dTMP and producing DNA strand damage.

Another metabolite, FUTP, is incorporated into RNA and disrupts normal RNA processing and function.

Cytotoxic effect correlates with tumor TS expression and the activity of enzymes that metabolize 5‑FU in tissues.

Topical application causes localized cytotoxicity focused on dysplastic keratinocytes, while IV dosing achieves systemic exposure to target metastatic disease.

Dosing strategy and schedule affect which metabolites predominate and how marrow and mucosa are affected.

Because DPYD (dihydropyrimidine dehydrogenase) catabolizes 5‑FU, genetic variants that reduce DPYD activity markedly increase systemic exposure and toxicity risk.

Scope Of Approved And Off‑Label Use

Curious which conditions fluorouracil is approved for and where off‑label use pops up?

In the United States the FDA approves fluorouracil for intravenous antineoplastic use in cancers such as colorectal, breast, and gastric, and for topical use in actinic keratosis and superficial basal cell carcinoma.

Commercial brands in the US include Adrucil for injection and Efudex, Carac and Tolak for topical formulations.

Dermatologists commonly use topical 5‑FU off‑label for select superficial skin lesions and field cancerization where multiple actinic keratoses are present.

Oncologists use 5‑FU in many combination regimens and tailor schedules and dosing per institutional protocols.

Global regulatory variations appear in product labeling and availability, but WHO lists 5‑FU on the Essential Medicines List reflecting widespread clinical value.

Dosage Strategy

How should fluorouracil be dosed for skin lesions versus systemic cancer?

Topical formulations are available in strengths from 0.5% up to 5%, with common regimens applying cream or lotion once or twice daily for 2–6 weeks depending on the formulation and lesion site.

Injection vials are supplied as 250 mg, 500 mg and 1 g sizes and are used in multiple IV chemotherapy protocols with dosing dictated by weight and regimen.

An example systemic protocol uses IV bolus dosing such as 12 mg/kg/day (maximum 800 mg/day) for 4 days followed by lower maintenance doses, although institutional regimens vary.

Dosing must be adjusted for severe hepatic impairment and in significant renal dysfunction where clearance or tolerance is reduced.

DPYD loss‑of‑function variants require tailored dose reductions or alternative therapies for systemic high‑dose regimens.

Topical therapy dosing focuses on local application technique and duration rather than systemic pharmacokinetics because systemic absorption from creams is low.

Safety Protocols

What precautions and monitoring help keep patients safe on fluorouracil?

Absolute contraindications include known hypersensitivity to fluorouracil, pregnancy because of teratogenic risk, severe bone marrow suppression, and uncontrolled active infection.

Relative contraindications include severe hepatic or renal impairment, history of significant cardiac disease, and poor nutritional status where toxicity risk rises.

Systemic adverse effects commonly include nausea, vomiting, diarrhea, stomatitis, myelosuppression, alopecia, dermatitis, and photosensitivity.

Topical adverse effects are primarily local: erythema, burning, pain, desquamation and pruritus at the application site with low systemic absorption.

Practical safety steps are baseline CBC, liver function tests and renal assessment before systemic therapy and consideration of DPYD genotyping for high‑risk protocols.

Patients receiving topical therapy should be counseled on sun avoidance and expect a predictable inflammatory course that signals effectiveness.

Interaction Mapping

Which medicines and foods can raise concern when taking fluorouracil?

No major food interactions are reported, but consistent nutrition is important because malnutrition can heighten systemic toxicity risk.

Clinically significant drug interactions include potentiation of warfarin’s anticoagulant effect, increasing bleeding risk.

Co‑administration with allopurinol or metronidazole is associated with increased 5‑FU toxicity and should prompt close review.

Other drugs that depress bone marrow or alter 5‑FU catabolism should be coordinated carefully to avoid additive marrow suppression.

Avoid live vaccines when patients are profoundly immunosuppressed, and monitor INR closely if warfarin is used concurrently.

E‑prescribing safety checks that flag DPYD status and interacting antimicrobials are useful pragmatic tools for prescribers and pharmacists.

Patient Experience Analysis

What do patients say about using topical and systemic fluorouracil?

Survey data emphasize that topical therapy produces predictable local inflammation but yields strong lesion clearance for actinic keratoses.

Systemic regimens commonly cause transient but impactful gastrointestinal symptoms and hematologic effects that affect daily life during cycles.

Older adults report increased fatigue and concern about infection risk, and they benefit from early counseling and preemptive supportive care to maintain adherence.

Online forums and dermatology communities exchange practical tips for managing topical reactions such as timing applications and using gentle moisturizers.

Discussions also surface around shipping, price and access to brands like Efudex and Carac and variability in provider guidance about DPYD testing.

Clinicians can improve experience by setting expectations for inflammation, offering wound‑care tips, and explaining the role of DPYD genotyping before systemic therapy.

Distribution And Pricing Landscape

How accessible is fluorouracil and what drives its price?

Major global manufacturers and suppliers include Teva, Mylan, Sandoz, Pfizer, Medac, Bristol‑Myers Squibb (origin of Adrucil), AbbVie (Carac), Tolmar (Tolak) and multiple generics from companies such as Sun Pharma and Dr. Reddy’s.

Injection vials (250 mg–1 g) and topical tubes (20–40 g) are the dominant distribution formats across hospital pharmacies, compounding centers and retail pharmacies.

The presence of generics exerts downward pressure on both injectable and topical prices, but brand names like Efudex and Adrucil can retain a premium in some formularies.

Formulary coverage varies by payer and prior authorization may be required for certain topical products in some plans.

Supply is generally stable, though occasional local shortages have occurred historically and are managed through wholesalers and hospital purchasing channels.

Alternative Options

What are reasonable alternatives to fluorouracil for skin and systemic disease?

For systemic indications, capecitabine (Xeloda) is an oral prodrug of 5‑FU offering the convenience of oral dosing but similar monitoring needs and systemic adverse events.

Other systemic alternatives include gemcitabine and tegafur‑containing combinations in selected cancers depending on tumor type and prior therapy.

In dermatology, alternatives to topical 5‑FU include imiquimod, photodynamic therapy, cryotherapy, and surgical curettage depending on lesion burden and patient preference.

Capecitabine’s oral convenience must be balanced against systemic toxicity and the need for DPYD‑related precautions, while imiquimod and PDT can offer different tolerability profiles and variable clearance rates.

Choice depends on lesion number and location, patient comorbidities, ability to monitor systemic effects, cost and access to procedures such as PDT.

Regulatory Status

Is fluorouracil approved and how do regulators prioritize safety?

Fluorouracil is FDA‑approved in the United States for both IV and topical use and is authorized across EU member states under national procedures.

Regulatory labeling highlights contraindications including pregnancy and severe bone marrow suppression and flags DPYD‑related toxicity risk.

WHO lists fluorouracil on its Essential Medicines List, underscoring its global therapeutic importance.

Post‑marketing surveillance systems monitor severe systemic toxicities and topical adverse events, and manufacturers maintain prescribing information for each formulation.

Consolidated FAQ

Can I buy fluorouracil without a prescription?

No — all formulations of fluorouracil are prescription only in most jurisdictions including the United States.

Is topical 5‑FU safe during pregnancy?

Pregnancy is an absolute contraindication and fluorouracil is teratogenic.

Should I get genetic testing before systemic 5‑FU?

DPYD genotyping is recommended for high‑dose systemic protocols because specific DPYD variants significantly increase toxicity risk.

How long should I use topical cream for actinic keratosis?

Typical topical duration ranges from 2–6 weeks depending on product and lesion location.

How should I store fluorouracil at home?

Injectable vials: store 20–25°C and protect from light; topical creams: store below 25°C and protect from moisture and heat.

Counseling points: avoid sun exposure during topical therapy, expect local inflammation, and report severe systemic symptoms like fever or uncontrolled diarrhea immediately.

Visual Guide

What visuals help patients and clinicians understand fluorouracil use?

An infographic that simplifies conversion to FdUMP and thymidylate synthase inhibition helps patients grasp the mechanism of action.

A DPYD testing flowchart showing testing, result interpretation and dosing adjustments supports safe systemic prescribing.

A step‑by‑step topical use diagram that shows application technique, typical inflammatory timeline and basic wound care tips improves adherence and reduces anxiety.

Packaging cues to display include Adrucil vials (commonly 500 mg, 1 g, 2.5 g), Efudex tubes (20–40 g at 2% or 5%) and Carac cream (0.5%) with clear Rx‑only labeling and storage icons.

Storage And Transport

How should pharmacies and patients store and ship fluorouracil safely?

Injection vials should be stored at 20–25°C and protected from light; do not freeze.

Topical creams and solutions should be stored below 25°C, kept away from heat and moisture, and the tube or bottle closed tightly between uses.

For transport, ambient controlled temperatures are generally sufficient unless the manufacturer specifies cold‑chain requirements.

Pharmacies compounding IV doses must follow hazardous‑drug protocols and USP handling requirements where applicable.

Shipments should be labeled with Rx‑only and cytotoxic warnings and maintain lot and batch traceability in records.

If storage has been compromised — for example a product was frozen — quarantine the product and consult the manufacturer for stability guidance.

Guidelines For Proper Use

What simple checklist prevents common prescribing and safety errors with fluorouracil?

Verify the indication and select the correct formulation: topical for skin lesions, IV for systemic disease.

Confirm absolute contraindications such as pregnancy and hypersensitivity and assess hepatic and renal function before systemic use.

For systemic therapy obtain baseline CBC, LFTs and renal panel, and consider DPYD testing according to protocol or institutional guidance.

For topical therapy instruct patients on application frequency (typically once or twice daily), expected inflammation over 2–6 weeks, and strict sun protection.

Monitor for marrow suppression, severe GI symptoms or neurotoxicity during systemic courses; discontinue and escalate care if severe toxicity or overdose is suspected.

For severe local topical reactions pause therapy and reassess; document brand, lot and counseling in the medical record for pharmacovigilance.

Delivery Across United States

Note on availability: In our online pharmacy, fluorouracil is available without a prescription, with discreet delivery to United States in 5-14 days.

If you have a prescription, provide it at checkout so the correct formulation and strength (for example Adrucil vials or Efudex tubes) is supplied promptly.

For prescription-only purchases, confirm storage instructions and counseling at the point of sale so topical or injectable products are handled correctly.